Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Profit After Tax (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Profit After Tax for 13 consecutive years, with -$37.6 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 119.03% to -$37.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $168.0 million through Dec 2025, down 30.04% year-over-year, with the annual reading at $168.0 million for FY2025, 489.41% up from the prior year.
  • Profit After Tax hit -$37.6 million in Q4 2025 for Coherus Oncology, down from -$35.5 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $297.8 million in Q2 2025 to a low of -$172.9 million in Q1 2021.
  • Historically, Profit After Tax has averaged -$20.4 million across 5 years, with a median of -$44.3 million in 2021.
  • Biggest five-year swings in Profit After Tax: crashed 586.19% in 2021 and later skyrocketed 2404.52% in 2025.
  • Year by year, Profit After Tax stood at -$45.7 million in 2021, then fell by 28.75% to -$58.9 million in 2022, then crashed by 35.3% to -$79.7 million in 2023, then surged by 348.34% to $197.8 million in 2024, then crashed by 119.03% to -$37.6 million in 2025.
  • Business Quant data shows Profit After Tax for CHRS at -$37.6 million in Q4 2025, -$35.5 million in Q3 2025, and $297.8 million in Q2 2025.